This is what inspires us. For a child suffering from a painful laceration or a person who can't see because of a cataract, they need their lives to get better, to feel normal again. We spend an inordinate amount of time developing a few drugs. We seek to enhance the lives of everyone we interact with. Follow us...

MSK-1001

MSK-1001 is an investigational topical gel that is applied onto a laceration and minimizes the pain associated with injecting a local anesthetic. The proprietary medicine is a sterile formulation of lidocaine, epinephrine, and tetracaine (also known in the medical literature as LET). Pharmacy-compounded versions of LET have been used in emergency departments of many hospitals for the past decade. We believe that many of these pharmacy-compounded LET products lack sterility, consistency, stability, and can be inappropriately multi-dosed and stored. We plan to develop the first FDA-approved LET product that is sterile, safe, efficacious, single-dosed, stable and consistently produced to high standards. Currently, there are no FDA-approved topical dermal analgesic products for minimizing the pain from a laceration.

Recently, there have been 58 deaths and 740 fungal meningitis cases resulting from a tainted injectable steroid that was formulated and mass produced by a single compounding pharmacy. MSK-1001 meets a vital clinical need as it will replace a non-sterile pharmacy compounded product with one that has been clinically tested for safety and efficacy and manufactured to sterile FDA standards.